Bortezomib:  days
Patients with hypersensitivity to bortezomib, boron or mannitol.
Known hypersensitivity to Velcade, boron, or mannitol
Current or anticipated use of other investigational agents; NOTE the following clarification for this study:\r\n* Prohibited concurrent therapy: \r\n** Participation in clinical trials with other investigational agents, not included in this trial, within  days of the start of this trial until  weeks after subject has received the last dose of bortezomib for mobilization\r\n** Hypersensitivity to bortezomib, boron or mannitol or G-CSF
Have a history of allergic (anaphylactic) sensitivity to bortezomib, boron or mannitol
Patient with hypersensitivity to bortezomib, boron or dexamethasone
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to any of the following: bortezomib, boron, mannitol
Previous history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Participant who has hypersensitivity to bortezomib, boron, or mannitol
Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate .
Patient has hypersensitivity to bortezomib, boron or mannitol
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Patients must not have hypersensitivity to bortezomib, boron or mannitol
History of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate  or sodium citrate dehydrate
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to bortezomib, boron, or mannitol
Known allergy to bortezomib, boron, or mannitol
Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Hypersensitivity to boron or mannitol, or compounds containing these components
Patient has hypersensitivity to bortezomib, boron or mannitol
History of allergic reactions to compounds containing boron, mannitol, VELCADE
Hypersensitivity to bortezomib, boron, or mannitol
Patient has hypersensitivity to bortezomib, boron, mannitol, gemcitabine, or doxorubicin. Gemcitabine skin rash that be controlled by short course steroids is allowed.
No history of hypersensitivity to bortezomib, boron or mannitol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Hypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapy
Known hypersensitivity to bortezomib, boron, or mannitol
Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.
Patient has hypersensitivity to bortezomib, boron or mannitol
Patient has a history of allergic reaction attributable to bortezomib or other compounds containing boron or mannitol (Phase b and a only)
a. bortezomib
Patients with hypersensitivity to bortezomib, boron or mannitol
Patients with hypersensitivity to bortezomib, boron or mannitol
